Objective: To summarize the experience in ameliorating curative resection rate and major postoperative complication rate for treatment of hilar cholangiocarcinoma.
Methods: Respective analysis was made on the clinical data of 54 consecutive cases who underwent resection of hilar cholangiocarcinoma from Jan. 1998 to Dec. 2004.
Results: In this group 54 cases received tumor resection with a resection rate of 63.5%. Combined partial hepatectomy was performed in 14 patients, while combined pancreaticoduodenectomy (Whipple) in 3 patients, and combined resection of portal vein in 2 patients and combined resection of hepatic artery in 2 patients. Thirty patients had curative resection. The curative resection rate was greatly increased from 27.0% (before 2001) to 41.7% (after 2001) in this group with well controlled perioperative mortality and postoperative complications rate (e.g. hepatic failure and major infection). The gross 1-, 2-, and 3-year survival rates for the whole group were 67.4%, 28.1% and 13.5% respectively. The 1-, 2-, and 3-year survival rates for curative resection were 87%, 36% and 24% respectively. The 1-, 2-year survival rates for palliative resection were 42% and 18%.
Conclusions: Enhanced surgical technique resulted in better clinical outcomes.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Techniques of Oncovascular Reconstruction of Portal and Mesenteric Veins during Pancreatic and Hepatobiliary Surgery.
Vasc Specialist Int
December 2024
Division of Vascular Surgery, Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
Major vessel invasion, particularly involving the portal and superior mesenteric veins, poses significant challenges during the radical resection of hepatobiliary and pancreatic cancers. Oncovascular surgery is essential for curative outcomes, and often requires portomesenteric vein reconstruction. Techniques, such as lateral venorrhaphy, patch repair, end-to-end anastomosis, and interposition grafting, have been employed.
View Article and Find Full Text PDFChallenges and Opportunities in Targeting the Complex Pancreatic Tumor Microenvironment.
JCO Oncol Adv
December 2024
Department of Surgery, Oregon Health & Science University, Portland, OR.
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths with a 5-year survival rate of 13%. Surgical resection remains the only curative option as systemic therapies offer limited benefit. Poor response to chemotherapy and immunotherapy is due, in part, to the dense stroma and heterogeneous tumor microenvironment (TME).
View Article and Find Full Text PDFPrognostic value of preoperative systemic immune-inflammation index/albumin for patients with hepatocellular carcinoma undergoing curative resection.
World J Gastroenterol
December 2024
Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China.
Background: Hepatocellular carcinoma (HCC) is a major factor for cancer-associated mortality globally. Although the systemic immune-inflammation index (SII) and albumin (ALB) show individual prognostic value for various cancers, their combined significance (SII/ALB) in HCC patients undergoing curative hepatectomy is still unknown. It is hypothesized that a higher SII/ALB ratio correlates with poorer outcomes with regard to overall survival (OS) and recurrence-free survival (RFS).
View Article and Find Full Text PDFAnalysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations.
Ther Adv Med Oncol
December 2024
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre (PMCC), University Health Network (UHN), 700 University Avenue, 7-812, Toronto, ON M5G 2M9, Canada.
Background: Given advancements in adjuvant treatments for non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)-targeted therapies, it is important to consider postoperative targeted therapies for other early-stage oncogene-addicted NSCLC. Exploring baseline outcomes for early-stage NSCLC with these rare mutations is crucial.
Objectives: This study aims to assess relapse-free survival (RFS) and overall survival (OS) in patients with resected early-stage NSCLC with rare targetable driver mutations.
Hepatocellular carcinoma converted from atezolizumab and bevacizumab combination therapy: a case report.
Oxf Med Case Reports
December 2024
Department of Gastroenterological and General Surgery, St. Marianna University School of Medicine, 2-16-1 Sugao Miyamae-ku, Kawasaki-shi, Kanagawa-ken 216-8511, Japan.
Hepatectomy is the curative treatment for hepatocellular carcinoma (HCC), with targeted therapy used when resection is difficult. In this rare case, the tumor shrank with targeted therapy, enabling radical treatment through conversion surgery. The patient, a man in his 70s, developed an 11.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!